GlassScriptPhysician profile
Jared Smedley
NPI 1487074191
$22,010.87
in general payments reported to CMS, 2019-2025
17 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.43 · 2021: $218 · 2022: $402 · 2023: $13K · 2024: $7,644 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,650 · Consulting Fee: $3,900 · Travel and Lodging: $3,408 · Food and Beverage: $2,399 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,950 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,650.00 |
| Consulting Fee | $3,900.00 |
| Travel and Lodging | $3,408.32 |
| Food and Beverage | $2,398.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,950.00 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,861.79 | 2022-2023 | Tepezza |
| Amgen INC. | $7,339.53 | 2024 | Tepezza |
| Alcon Vision LLC | $544.51 | 2019-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $407.50 | 2022-2025 | Durysta, Lumigan |
| Dompe US, INC. | $252.96 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $134.36 | 2024-2025 | Envista Envy Iol, Miebo, Vyzulta |
| Biotissue Holdings INC. | $125.45 | 2023 | |
| Sun Pharmaceutical Industries INC. | $94.21 | 2024-2025 | |
| Oyster Point Pharma, INC. | $47.90 | 2023-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $44.53 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $43.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.41 | 2022 | |
| Optos, INC. | $21.89 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.17 | 2023 | Flarex |
| Glaukos Corporation | $19.20 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $16.47 | 2025 | Iyuzeh |
| Ivantis, INC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Smedley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.